Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661859 | 0.76 | LMNA (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL6898698 | 0.76 | LMNA (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL154794 | 0.76 | ERN1 (0.61) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL29540911 | 0.75 | — | — | |
| SCHEMBL30039913 | 0.75 | — | — | |
| SCHEMBL20465749 | 0.75 | — | — | |
| SCHEMBL87096 | 0.75 | — | — | |
| SCHEMBL652253 | 0.74 | ERN1 (0.59) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL577856 | 0.74 | — | — | |
| Ammonia Solution, Strong SCHEMBL30950130 | 0.73 | MEN1 (0.60) | ERN1MEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102781942-A | Disubstituted octahy-dropyrrolo [3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | claimed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| CN-103582637-B | Tyrosine kinase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-12 | — | — | CN | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-101137641-B | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RES INST CHEM TECH | 2010-11-24 | — | — | CN | disclosed |
| US-20100160632-A1 | BISAMID-ZINKBASEN | LUDWIG MAXIMILIANS UNIVERSITAT MUNCHEN | 2010-06-24 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| CN-101137641-A | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RES INST CHEM TECH (KR) | 2008-03-05 | — | — | CN | disclosed |
| CN-1170804-C | Ortho-substituted benzaldehyde, its preparing method and use | 科莱恩有限公司 | 2004-10-13 | — | — | CN | disclosed |
| CN-1339428-A | Ortho-substituted benzaldehyde, its preparing method and use | CLARIANT GMBH (DE) | 2002-03-13 | — | — | CN | disclosed |
| CN-1070173-C | Benzoylguanidine derivatives as medicaments | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1158606-A | Benzoylguanidine derivatives as medicaments | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-09-03 | — | — | CN | disclosed |
| CN-1152853-A | Fungicidal compositions based on 3-phenylpyrazole derivatives for treating plant propagation material, novel 3-phenylpyrazole derivatives and their fungicidal use | RHONE POULENC AGROCHIMIE (FR) | 1997-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | ERN1 1201/4885MEN1 332/4885LMNA 2677/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | ERN1 439/4885MEN1 194/4885LMNA 1370/4885 |
| US-20100160632-A1 | BISAMID-ZINKBASEN | ZFX, ZRANB2, MLX | ERN1 3465/4885MEN1 1906/4885LMNA 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.